[1] FROMMEYER G, ECKARDT L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms[J]. Nat Rev Cardiol, 2016,13(1):36-47.
[2] SELZER A, WRAY H W. Quinidine syncope paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias[J]. Circulation, 1964, 30:17-26.
[3] BARNES B J, HOLLANDS J M. Drug-induced arrhythmias[J]. Crit Care Med, 2010, 38(6 suppl):188-197.
[4] ANTZELEVITCH C, YAN G X, SHIMIZU W. Transmural dispersion of repolarization and arrhythmogenicity:the Brugada syndrome versus the long QT syndrome[J]. J Electrocardiol, 1999, 32(S1):158-165.
[5] YAN G X, SHIMIZU W, ANTZELEVITCH C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations[J]. Circulation, 1998, 98(18):1921-1927.
[6] HUANG C L. Murine electrophysiological models of cardiac arrhythmogenesis[J]. Physiol Rev, 2017, 97(1):283-409.
[7] LI W, WANG Y P, GAO L, et al. Resveratrol protects rabbit ventricular myocytes against oxidative stress-induced arrhythmogenic activity and Ca²⁺ overload[J]. Acta Pharmacol Sin(中国药理学报), 2013, 34(9):1164-1173.
[8] LAVERTY H, BENSON C, CARTWRIGHT E, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?[J]. Br J Pharmacol, 2011, 163(4):675-693.
[9] WANG J F. Advance of improvement of the prediction on cardiovascular toxicity[J]. Chin J New Drugs(中国新药杂志), 2017, 26(23):2753-2758.
[10] ONAKPOYA I J, HENEGHAN C J, ARONSON J K. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions:a systematic review of the world literature[J]. BMC Med, 2016, 14:10.
[11] UVELIN A, PEJAKOVIC J, MIJATOVIC V. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia:a narrative review for the anesthesiologist and intensivist[J]. J Anesth, 2017, 31(3):413-423.
[12] WANG L F, YING Y Q, ZHAO L, et al. Effects of taurine-magnesium coordination compound on sodium channel in rat cardiomyocytes of arrhythmia induced by aconitine[J]. Chin Pharmacol Bull (中国药理学通报), 2010, 26(5):611-614.
[13] ZHU J, WANG M, ZHU Y. Quantitative cardiotoxicity assessment of gambogic acid using multiple cellular phenotype analysis[J]. Chin J Pharmacol Toxicol (中国药理学与毒理学杂志), 2017, 31(1):73-79.
[14] DANIELSSON C, BRASK J, SKÖLD A C, et al. Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism[J]. Cardiovasc Res, 2013,97(1):23-32.
[15] TERTOOLEN L G J, BRAAM S R, VAN MEER B J, et al. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes[J]. Biochem Biophys Res Commun, 2018, 497(4):1135-1141.
[16] HARARY I, FARLEY B. In vitro studies of single isolated beating heart cells[J]. Science, 1960, 131(3414):1674-1675.
[17] JUDD J, LOVAS J, HUANG G N. Isolation, culture and transduction of adult mouse cardiomyocytes[J]. J Vis Exp, 2016, (114):54012. doi:10.3791/54012.
[18] GAO H, QIAO H W. Use of transgeneic animals in toxicology[J]. Acta Lab Anim Sci Sin(中国实验动物学报), 2011, 19(6):544-547.
[19] NGUYEN N, NGUYEN W, NGUYENTON B, et al. Adult human primary cardiomyocyte-based model for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risk[J]. Front Physiol, 2017, 8:1073.
[20] NODA T, SHIMIZU W, SATOMI K, et al. Classification and mechanism of torsade de pointes initiation in patients with congenital long QT syndrome[J]. Eur Heart J, 2004, 25(23):2149-2154.
[21] UNDROVINAS A I, BELARDINELLI L, UNDROVINAS N A, et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current[J]. J Cardiovasc Electrophysiol, 2006, 17(S1):S169-s177.
[22] MILAN D J, SAUL J P, SOMBERG J C, et al. Effects of dalfampridine and its metabolites on cloned human potassium channels Kv 1.1, Kv 1.2, and Kv 1.4 expressed in human embryonic kidney cells[J]. Cardiology, 2017, 136(1):52-60.
[23] HARAGUCHI Y, OHTSUKI A, OKA T, et al. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp[J]. BMC Pharmacol Toxicol, 2015,16:39.
[24] GINTANT G, SAGER P T, STOCKBRIDGE N. Evolution of strategies to improve preclinical cardiac safety testing[J]. Nat Rev Drug Discov, 2016, 15(7):457-471.
[25] LEE A, PICKHAM D. Basic cardiac electrophysiology and common drug-induced arrhythmias[J]. Crit Care Nurs Clin North Am, 2016, 28(3):357-371.
[26] CHANDRASEKHAR S, FRADLEY M G. QT Interval prolongation associated with cytotoxic and targeted cancer therapeutics[J]. Curr Treat Options Oncol, 2019,20(7):55.
[27] POLLARD C E, SKINNER M, LAZIC S E, et al. An analysis of the relationship between preclinical and clinical QT interval-related data[J]. Toxicol Sci, 2017,159(1):94-101.
[28] RODEN D M. Predicting drug-induced QT prolongation and torsades de pointes[J]. J Physiol, 2016,594(9):2459-2468.
[29] ABRAHAM J M, SALIBA W I, VEKSTEIN C, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter[J]. Circ Arrhythm Electrophysiol, 2015, 8(4):772-776.
[30] VICENTE J, JOHANNESEN L, MASON J W, et al. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil[J]. J Am Heart Assoc, 2015, 4(4):1-13.
[31] CUBEDDU L X. Drug-induced inhibition and trafficking disruption of ion channels:pathogenesis of QT abnormalities and drug-induced fatal arrhythmias[J]. Curr Ardiol Rev, 2016, 12(2):141-154.
[32] VAN NOORD C, STURKENBOOM M C, STRAUS S M, et al. Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death[J]. Heart, 2011, 97(3):215-220.
[33] GINTANT G, SAGER P T, STOCKBRIDGE N. Evolution of strategies to improve preclinical cardiac safety testing[J]. Nat Rev Drug Discov, 2016, 15(7):457-471.
[34] Gintant G. Goals of Cipa: the comprehensive In Vitro Proarrhythmia Assay[EB/OL]. [2020-01-10]. https://www.fda.gov/media/104648/download.
[35] CRUMB W J J R, VICENTE J, JOHANNESEN L, et al. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel[J]. J Pharmacol Toxicol Methods, 2016, 81:251-262.
[36] KARAKIKES I, AMEEN M, TERMGLINCHAN V, et al. Human induced pluripotent stem cell-derived cardiomyocytes:insights into molecular, cellular, and functional phenotypes[J]. Circ Res, 2015,117(1):80-88.
[37] ANSON B D, KOLAJA K L, KAMP T J. Opportunities for use of human iPS cells in predictive toxicology[J]. Clin Pharmacol Ther, 2011, 89(5):754-758.
[38] HIGA A, HOSHI H, YANAGISAWA Y, et al. Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis[J]. J Toxicol Sci, 2017, 42(6):755-761.
[39] SALLAM K, LI Y, SAGER P T, et al. Finding the rhythm of sudden cardiac death:new opportunities using induced pluripotent stem cell-derived cardiomyocytes[J]. Circ Res, 2015, 116(12):1989-2004.
[40] KADOTA S, MINAMI I, MORONE N, et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets[J]. Eur Heart J, 2013, 34(15):1147-1156.
[41] QU Y, GAO B, FANG M, et al. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay[J]. J Pharmacol Toxicol Methods, 2013, 68(1):74-81.
[42] ANDO H, YOSHINAGA T, YAMAMOTO W, et al. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes[J]. J Pharmacol Toxicol Methods, 2017, 84:111-127.
[43] REDFERN W S, CARLSSON L, DAVIS A S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs:evidence for a provisional safety margin in drug development[J]. Cardiovasc Res, 2003, 58(1):32-45.
[44] MIRAMS G R, CUI Y, SHER A, et al. Simulation of multiple ion channel block provides improved early prediction of compounds′ clinical torsadogenic risk[J]. Cardiovasc Res, 2011, 91(1):53-61.
[45] KRAMER J, OBEJERO-PAZ C A, MYATT G, et al. MICE models:superior to the herg model in predicting torsade de pointes[J]. Sci Rep, 2013, 3:2100.
[46] OSADCHII O E. Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart[J]. Scand Cardiovasc J, 2016, 50(1):28-35.
[47] JUREVICIUS J, MUCKUS K, MACIANSKIENE R, et al. Influence of action potential duration and resting potential on effects of quinidine, lidocaine and e thmozin on V_max in guinea-pig papillary muscles[J]. J Mol Cell Cardiol, 1991, 23(S1):103-114.
[48] EDVARDSSON N, OLSSON S B. Clinical value of plasma concentrations of antiarrhythmic drugs[J]. Eur Heart J, 1987, 8(suppl A):83-89.
[49] ELAJNAF T, BAPTISTA-HON D T, HALES T G. Potent inactivation-dependent inhibition of adult and neonatal NaV1.5 channels by lidocaine and levob upivacaine[J]. Anesth Analg, 2018, 127(3):650-660.
[50] BRAAM S R, PASSIER R, MUMMERY C L. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery[J]. Trends Pharmacol Sci, 2009, 30(10):536-545.
[51] DE LANGE E, XIE Y, QU Z. Synchronization of early afterdepolarizations and arrhythmogenesis in heterogeneous cardiac tissue models[J]. Biophys J, 2012, 103(2):365-373.
[52] DE GREGORIO C, MORABITO G, CERRITO M, et al. Citalopram-induced long QT syndrome and torsade de pointes:role for concomitant therapy and disease[J]. Int J Cardiol, 2011, 148(2):226-228.
[53] YU Y, ZHANG M, CHEN R, et al. Action potential response of human induced-pluripotent stem cell derived cardiomyocytes to the 28 CiPA compounds: a non-core site data report of the CiPA study[J]. J Pharmacol Toxicol Methods, 2019, 98:106577.
[54] KANG J, CHEN X L, WANG H, et al. Cardiac ion channel effects of tolterodine[J]. J Pharmacol Exp Ther, 2004, 308(3):935-940.
[55] WEISSENBURGER J, FUNCK-BRENTANO C, JAILLON P, et al. Droperidol and ondansetron in vitro electrophysiological drug interaction study[J]. Fundam Clin Pharmacol, 2009, 23(6):719-726.
[56] SCHEEL O, FRECH S, AMUZESCU B, et al. Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology[J]. Assay Drug Dev Technol, 2014, 12(8):457-469.
[57] ANTZELEVITCH C, BURASHNIKOV A, SICOURI S, et al. Electrophysiologic basis for the antiarrhythmic actions of ranolazine[J]. Heart Rhythm, 2011, 8(8):1281-1290.
[58] WAGENLEHNER F M, KEES F, WEIDNER W, et al. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers[J]. Int J Antimicrob Agents, 2008, 31(1):21-26.
[59] HONDA M, KIYOKAWA J, TABO M, et al. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells[J]. J Pharmacol Sci, 2011, 117(3):149-159.
[60] DAVIS R P, VAN DEN BERG C W, CASINI S, et al. Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development[J]. Trends Mol Med, 2011, 17(9):475-484.
[61] JIANG Y, PARK P, HONG S M, et al. Maturation of cardiomyocytes derived from human pluripotent stem cells:current strategies and limitations[J]. Mol Cells, 2018, 41(7):613-621.
[62] KITAGUCHI T, MORIYAMA Y, TANIGUCHI T, et al. CSAHi study: evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities[J]. J Pharmacol Toxicol Methods, 2016, 78:93-102.
[63] KAWATOU M, MASUMOTO H, FUKUSHIMA H, et al. Modelling torsade de pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue[J]. Nat Commun, 2017, 8(1):1078.